IJCOPE Journal

UGC Logo DOI / ISO Logo

International Journal of Creative and Open Research in Engineering and Management

A Peer-Reviewed, Open-Access International Journal Supporting Multidisciplinary Research, Digital Publishing Standards, DOI Registration, and Academic Indexing.
Journal Information
ISSN: 3108-1754 (Online)
Crossref DOI: Available
ISO Certification: 9001:2015
Publication Fee: 599/- INR
Compliance: UGC Journal Norms
License: CC BY 4.0
Peer Review: Double Blind
Volume 02, Issue 11

Published on: November 2026

FINANCIAL PERFORMANCE AND OPERATING LEVERAGE IN SELECTED INDIAN PHARMACEUTICAL FIRMS

Adit Vijay Bhoite

Shirly Abraham

MBA (Finance), School of Business, Indira University, Pune, Maharashtra, India

Article Status

Plagiarism Passed Peer Reviewed Open Access

Available Documents

Abstract

This descriptive study examines how revenue growth, operating profitability and the observed sensitivity of EBITDA to revenue differ across five purposively selected listed Indian pharmaceutical firms (Piramal Pharma, Ajanta Pharma, Laurus Labs, Neuland Laboratories and Innova Captab) over FY2022–FY2026, and analyses Piramal Pharma’s FY2026 results in more detail. It uses audited consolidated results, revenue CAGRs, calculated EBITDA margins (excluding other income), margin variability, an ex post EBITDA-based operating-leverage proxy and a DuPont decomposition of return on equity. Revenue CAGRs ranged from 7.8% to 20.8%. Mean calculated EBITDA margins were 25.9% (Ajanta), 23.6% (Neuland) and 23.1% (Laurus), against 13.7% (Innova) and 12.8% (Piramal). Firms described as having stronger differentiated capabilities generally recorded higher average margins; this association does not establish causality. In FY2026 Piramal’s company-reported EBITDA fell 28.2% on a 3.1% revenue decline and PAT turned to a loss of INR 326 crore; an EBITDA-to-PAT bridge shows several contributing items, and return on average equity fell from 1.14% to −4.00%, mainly through net margin. Findings are limited to the sample, and MSME evidence is treated as context only.

How to Cite this Paper

Bhoite, A. V. (2026). Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(11), 1-9. https://doi.org/10.55041/ijcope.v2i11.093

Bhoite, Adit. "Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 11, 2026, pp. 1-9. doi:https://doi.org/10.55041/ijcope.v2i11.093.

Bhoite, Adit. "Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms." International Journal of Creative and Open Research in Engineering and Management 02, no. 11 (2026): 1-9. https://doi.org/https://doi.org/10.55041/ijcope.v2i11.093.

Search & Index

References

Abrol, D. K., John, R., & Singh, N. (2026). The quality challenge for generic medicines in India: An industrial policy-sensitive perspective. Indian Journal of Medical Ethics, 11(2). https://doi.org/10.20529/IJME.2026.017

Ajanta Pharma Limited. (2022, May 10). Statement of consolidated audited financial results for the quarter and year ended 31 March 2022 [Exchange filing, PDF pp. 4–5].

https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/PressReleaseQ4%28Jan-Mar%292021-22.pdf

Ajanta Pharma Limited. (2024, May 2). Statement of consolidated audited financial results for the quarter and year ended 31 March 2024 [Exchange filing, PDF pp. 4–5].

https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/PressRelease-Q4FY2024.pdf

Ajanta Pharma Limited. (2026, May 5). Statement of consolidated audited financial results for the quarter and year ended 31 March 2026 [Exchange filing, PDF pp. 4–5].

https://www.ajantapharma.com/assets/frontend/images/inv estors/files/quarterly_results/1777975848_PressRelease-Q4FY2026.pdf

Anderson, M. C., Banker, R. D., & Janakiraman, S. N. (2003). Are selling, general, and administrative costs “sticky”? Journal of Accounting Research, 41(1), 47–63. https://doi.org/10.1111/1475-679X.00095

Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99–120.

BSE Limited. (2024, July 2). Piramal Pharma Limited: Notice of 4th AGM and annual report 2023–24 [Exchange filing]. https://bseindia.com/xml-data/corpfiling/AttachHis/c09d72ec-f184-4eba-bcc8-93b26b846609.pdf

Business Standard. (2025, December 25). Just 1 in 4 MSME pharma units set for GMP transition as deadline nears. https://www.business-standard.com/industry/news/only-one-fourth-msme-drugmakers-comply-gmp-schedule-m-india-125122500521_1.html

Ethical Compliance & Review Process

  • •All submissions are screened under plagiarism detection.
  • •Review follows editorial policy.
  • •Authors retain copyright.
  • •Peer Review Type: Double-Blind Peer Review
  • •Published on: Nov 17 2026
CCBYNC

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.

View License
Scroll to Top